Skip to main content

Type 2 diabetes

medwireNews top story

Women with diabetes need system-wide change to improve pregnancy outcomes

Data from the first 5 years of the UK’s National Pregnancy in Diabetes audit reveal differing effects of type 1 and type 2 diabetes on pregnancy outcomes, with no sign of improvements over time.

medwireNews top story

Glycemic benefits of metabolic surgery endure for at least 10 years

Metabolic surgery can result in type 2 diabetes remission lasting for at least 10 years, and people who relapse still achieve markedly improved glycemic control, shows follow-up from a randomized trial published in The Lancet.

medwireNews top story

AWARD 11 supports higher dulaglutide doses

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

medwireNews top story

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

medwireNews top story

Support for bariatric surgery in people with insulin-dependent type 2 diabetes

Treatment with bariatric surgery is associated with clinical and cost-saving benefits among obese people with type 2 diabetes requiring insulin, researchers report.

medwireNews top story

Metformin might protect women with type 2 diabetes against COVID-19 mortality

An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.

medwireNews top story

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

medwireNews top story

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

medwireNews top story

Rural inhabitants may miss out on newest diabetes medications

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

medwireNews top story

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

24-10-2023 | Type 2 diabetes | News

Prediabetes remission with lifestyle intervention reduces type 2 diabetes risk

A post-hoc analysis of the German Prediabetes Lifestyle Intervention Study has found that people who achieve remission of prediabetes by losing weight through lifestyle intervention for 12 months may reduce their risk for developing type 2 diabetes.

05-10-2023 | Type 2 diabetes | News

ONWARDS 5: Weekly insulin icodec with app shows real-world promise for type 2 diabetes

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

25-09-2023 | Gestational diabetes | News

Gestational diabetes independently linked to increased future mortality risk

Women with a history of gestational diabetes have a significantly increased risk for long-term mortality regardless of whether or not they subsequently developed type 2 diabetes.

20-09-2023 | Latent autoimmune diabetes of adulthood | News

Latent autoimmune diabetes carries mortality and CVD risks comparable to type 2 diabetes

Latent autoimmune diabetes in adults is associated with similar risks for mortality and cardiovascular disease and an increased risk for retinopathy compared with type 2 diabetes.

15-09-2023 | Type 2 diabetes | News

Young-onset type 2 diabetes diagnosis linked to shortened life expectancy

Younger age at type 2 diabetes diagnosis is associated with shorter life expectancy, with 3 to 4 years lost for every decade of earlier diagnosis.

04-09-2023 | Type 2 diabetes | News

New model predicts kidney disease progression risk in type 2 diabetes

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

31-08-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Gastric bypass surgery (used with permission)

28-07-2023 | Type 2 diabetes | News

Better QoL after gastric bypass than sleeve gastrectomy for people with type 2 diabetes

Patients undergoing gastric bypass experience superior patient-reported outcomes, diabetes remission rates and weight loss compared with sleeve gastrectomy.

20-07-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

14-07-2023 | Type 2 diabetes | News

Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

07-07-2023 | Type 2 diabetes | News

New atherothrombotic risk score for type 2 diabetes

The TIMI Risk Score for Atherothrombosis in Diabetes categorises risk of myocardial infarction or stroke in people with type 2 diabetes.

Doctor measures a man's waist

03-07-2023 | Type 2 diabetes | News

‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

22-06-2023 | Cardiovascular outcomes | News

Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

05-06-2023 | Prediabetes | News

Caloric restriction outperforms liraglutide for weight loss in prediabetes

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.